We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00672659
Recruitment Status : Completed
First Posted : May 6, 2008
Last Update Posted : May 2, 2011
Information provided by:
PharmaNeuroBoost N.V.

Brief Summary:

The primary objective is to demonstrate whether the addition of pipamperone 5 mg twice daily (bd) to citalopram, 40 mg daily in patients suffering from MDD will improve the efficacy of citalopram 40 mg in these patients.

Secondary objectives are to demonstrate whether the addition of pipamperone 5 mg twice daily (bd) to citalopram, 40 mg daily in patients suffering from MDD:

  1. Will increase the rate of resolution of symptoms with citalopram 40 mg.
  2. Show the combined product to be safe and tolerable.

Patients are scheduled to receive study medication for eight weeks and a final follow-up check will be carried out 28 days after completing the study.

All patients will receive active citalopram from baseline and will be randomised to receive either active pipamperone or a placebo equivalent for eight weeks during which time they will attend for 6 study visits.

Condition or disease Intervention/treatment Phase
Depression Drug: Citalopram + Pipamperone Drug: Citalopram Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 165 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase IIa Proof of Concept Study of Pipamperone/Citalopram (PipCit) Versus Citalopram in the Treatment of Major Depressive Disorder (MDD)
Study Start Date : February 2008
Actual Primary Completion Date : January 2009
Actual Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1
Citalopram, 40 mg daily in combination with Pipamperone, 5 mg twice daily (bd)
Drug: Citalopram + Pipamperone
Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks

Placebo Comparator: 2
Citalopram, 40 mg daily in combination with Placebo, dummy twice daily (bd)
Drug: Citalopram
Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks

Primary Outcome Measures :
  1. Change in Montgomery-Asberg Depression Rating Scale score [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. The number of patients showing evidence of onset of action defined as a 20% improvement from baseline MADRS [ Time Frame: At Weeks 1 and 2 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female patients
  • 18-65 years inclusive
  • Suffering from a moderate to severe MDD as defined by DSM IV with an existence of depressed mood and loss of interest/anhedonia for at least four weeks and no longer than six months for the current episode
  • Diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI) version 5.0.0.
  • Clinical global impression - severity scale (CGI-S) rating of at least four and a minimum Hamilton Depression Scale (HAM-D) 17 items total score of 18 at screen and baseline
  • A non-psychotic state
  • Where appropriate, male patients should agree to use barrier contraceptive measures (condoms) during the course of the study and for three months after the last dose of medication

Exclusion Criteria:

  • Premenopausal females not using adequate contraceptive measures
  • Considered by the investigator to be a significant risk of suicide or scoring 5 or more on the MADRS question 10
  • Significant other psychiatric illness which would interfere with trial assessments - co-morbid generalised anxiety disorder (GAD) and panic disorder will be permitted where MDD is considered the primary diagnosis
  • Significant physical illness which would interfere with trial assessments
  • Reduced hepatic function
  • Epilepsy
  • History of cardiac dysrhythmia
  • Alcohol intake above accepted UK ranges
  • Recent (1 week) antidepressant (except for fluoxetine - 4 weeks and St John's Wort or MAOI's - 14 days), benzodiazepine or any other psychotropic medication ingestion including lithium or other mood stabilisers
  • Resistant depression defined as having failed to respond to

    • Two previous antidepressants at an adequate dose ingested for at least 4 weeks during the current episode
    • To an augmentation therapy with an atypical antipsychotic drug
  • Electroconvulsive therapy (ECT) for the current episode
  • Formal psychotherapy or alternative treatments for one week prior to or during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00672659

Layout table for location information
United Kingdom
Glasgow, Scotland, United Kingdom, G20 0XA
Sponsors and Collaborators
PharmaNeuroBoost N.V.
Layout table for investigator information
Study Chair: Erik Buntinx, MD PharmaNeuroBoost N.V.
Study Director: Alan Wade, MG CPSResearch
Principal Investigator: Gordon Crawford, MD CPSResearch
Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Erik Buntinx, MD, PharmaNeuroBoost N.V.
ClinicalTrials.gov Identifier: NCT00672659    
Other Study ID Numbers: PNB/CPS 02 2007
First Posted: May 6, 2008    Key Record Dates
Last Update Posted: May 2, 2011
Last Verified: April 2011
Keywords provided by PharmaNeuroBoost N.V.:
Lost of interest, Depressed Mood
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Serotonin Antagonists
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants